FLT3 and acute myeloid leukemia: Clonal evolution of the disease could be especially relevant for treatment response [26,27], and in relapsed AML patients, our results supported that molecular testing should be conducted again in order to identify targetable abnormalities such as FLT3 mutations, which showed a stability rate of 43.3% in our cohort [28].